Literature DB >> 15944006

Galnon--a low-molecular weight ligand of the galanin receptors.

Ulla Sollenberg1, Tamas Bartfai, Ulo Langel.   

Abstract

Galnon is a low-molecular weight galanin receptor ligand, with affinity towards the three galanin receptors in the micromolar range. Galnon is of interest as a drug candidate due to its stability and ability to pass the blood-brain barrier. Like galanin, galnon has also been shown to affect various physiological functions; however, occasionally galanin and galnon act in opposing ways. Since its introduction in 2002, galnon has been characterized to inhibit seizures, decrease feeding behaviour, diminish physical signs of opiate withdrawal and to alleviate heat-hyperalgesic response to partial sciatic nerve injury. In this review, we will summarize what is known about galnon to date.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15944006     DOI: 10.1016/j.npep.2004.12.019

Source DB:  PubMed          Journal:  Neuropeptides        ISSN: 0143-4179            Impact factor:   3.286


  6 in total

1.  Neuropeptide receptor positive allosteric modulation in epilepsy: galanin modulation revealed.

Authors:  Daniel Hoyer
Journal:  Proc Natl Acad Sci U S A       Date:  2010-08-16       Impact factor: 11.205

2.  Synthesis and biological evaluation of novel pyrimidine derivatives as sub-micromolar affinity ligands of GalR2.

Authors:  Vasudeva Naidu Sagi; Tianyu Liu; Xiaoying Lu; Tamas Bartfai; Edward Roberts
Journal:  Bioorg Med Chem Lett       Date:  2011-09-25       Impact factor: 2.823

3.  The neuropeptide galanin and variants in the GalR1 gene are associated with nicotine dependence.

Authors:  Kia J Jackson; Xiangning Chen; Michael F Miles; JoLynne Harenza; M Imad Damaj
Journal:  Neuropsychopharmacology       Date:  2011-07-27       Impact factor: 7.853

4.  Regulation of glucose and insulin release following acute and repeated treatment with the synthetic galanin analog NAX-5055.

Authors:  Sean P Flynn; H Steve White
Journal:  Neuropeptides       Date:  2015-01-21       Impact factor: 3.286

5.  The galanin receptor agonist, galnon, attenuates cocaine-induced reinstatement and dopamine overflow in the frontal cortex.

Authors:  Yvonne E Ogbonmwan; Natale R Sciolino; Jessica L Groves-Chapman; Kimberly G Freeman; Jason P Schroeder; Gaylen L Edwards; Philip V Holmes; David Weinshenker
Journal:  Addict Biol       Date:  2014-07-23       Impact factor: 4.280

Review 6.  Alteration of epileptogenesis genes.

Authors:  Amy R Brooks-Kayal; Yogendra H Raol; Shelley J Russek
Journal:  Neurotherapeutics       Date:  2009-04       Impact factor: 7.620

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.